Remote CRA II for IBD Trials (Contract)

PSI CRO; Lisboa; On-site; EUR 30,000 - 52,000; Part time

Job summary

PSI CRO is seeking a Clinical Research Associate II for a contract-based, home-based freelance position in Portugal. You will monitor sites, support startup, review CRFs, manage communications, and ensure data quality across multiple studies.

The role requires strong English/Portuguese skills and willingness to travel. Ideal candidates have at least 1 year of independent on-site monitoring in Portugal, experience with Phase II/III monitoring, and exposure to IBD studies.

Qualifications

• 1 year of independent on-site monitoring experience in Portugal.
• Experience in all types of monitoring visits in Phase II and/or III.
• Experience in IBD/Inflammatory Bowel Diseases is mandatory.
• Full working proficiency in English and Portuguese.
• Ability to travel.

Responsibilities

• Conduct and report all types of onsite monitoring visits
• Be involved in study startup
• Perform CRF review, source document verification and query resolution
• Be responsible for site communication and management
• Supervise study activities, timelines, and schedules on the country level
• Be a point of contact for in-house support services and vendors
• Be involved in quality control, such as compliance monitoring and reports review
• Participate in feasibility research
• Support regulatory team in preparing documents for study submissions

Skills

On-site monitoring

English language

Portuguese language

Communication

Multitasking

Team collaboration

Travel flexibility

Education

Bachelor's degree in Life Sciences

Tools

MS Office

Job description

PSI CRO is seeking a Clinical Research Associate II for a contract-based, home-based freelance position in Portugal. You will monitor sites, support startup, review CRFs, manage communications, and ensure data quality across multiple studies.

The role requires strong English/Portuguese skills and willingness to travel. Ideal candidates have at least 1 year of independent on-site monitoring in Portugal, experience with Phase II/III monitoring, and exposure to IBD studies.